Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 69

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Testosterone Therapy Can Enhance Erectile Function Response to Sildenafil in Patients with PADAM: A Pilot Study

Shamloul, Rany, Ghanem, Hussein, Fahmy, Ibrahim, El-Meleigy, Amr, Ashoor, Shedeed, Elnashaar, Abdelrahman, Kamel, Ihab·2005·The Journal of Sexual Medicine
DOI 10.1111/j.1743-6109.2005.00071.x
Open this paper in CoChat — free account

Abstract

Introduction: Recent studies suggest a direct relationship between free testosterone and cavernous vasodilatation. Some men with erectile dysfunction (ED) associated with PADAM (partial androgen deficiency in aging men) might possibly benefit from testosterone undecanoate therapy (TRT). Objectives: To determine the efficacy of testosterone undecanoate in facilitating the erectile response and patient satisfaction with sildenafil in men 40–70 years old with PADAM symptoms. Design and Methods: Prospective study including 40 patients recruited after a sildenafil therapeutic trial. Total testosterone and sex hormone binding globulin (SHBG) were measured to calculate the free androgen index. Prostate specific antigen (PSA) was measured and repeated 2 months after treatment. A rating score was used for PADAM symptoms, and the 5-point abbreviated version of the International Index of Erectile Function (IIEF-5) to assess erectile function. Men failing to respond to sildenafil were randomized into two groups receiving sildenafil plus continuous TRT (group 1ST), and TRT (group 1T) alone. Men partially responding to sildenafil were randomized into two groups receiving sildenafil plus continuous TRT for 2 months (group 2ST), or sildenafil alone (group 2S). Treatment efficacy was assessed by analysis of between-group differences. Results: Groups 1T, 2S, and 2ST showed significant improvement in PADAM scores (P < 0.05, Wilcoxon matched pairs test). Patients receiving both sildenafil plus continuous TRT (groups 1ST and 2ST) showed significant improvement in IIEF-5 scores (P < 0.5, paired t-test). No significant changes in serum levels of PSA were detected (paired t-test). Conclusions: We conclude that TRT appears to be beneficial and safe in facilitating the erectile response and patient satisfaction with sildenafil in men with PADAM symptoms. Androgen supplementation should be carried out cautiously with careful monitoring to avoid possible adverse effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1743-6109.2005.00071.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 18

  1. Palumbo, 2001, Sildenafil: Efficacy and safety in daily clinical experience, Eur Urol, 40, 176, 10.1159/000049769 · DOI
  2. Aversa, 2000, Androgens and penile erection: Evidence for a direct relationship between free testosterone and cavernous vasodilatation in men with erectile dysfunction, Clin Endocrinol, 53, 517, 10.1046/j.1365-2265.2000.01118.x · DOI
  3. Guay, 2001, Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in a population with associated organic risk factors, J Androl, 22, 793, 10.1002/j.1939-4640.2001.tb02582.x · DOI · Paper page
  4. Comhaire, 2000, Andropause: Hormone replacement therapy in the ageing male, Eur Urol, 38, 655, 10.1159/000020358 · DOI
  5. Van Den Beld, 2000, The male climacterium: Clinical signs and symptoms of a changing endocrine environment, Prostate, 10, 2, 10.1002/1097-0045(2000)45:10+<2::AID-PROS2>3.0.CO;2-Y · DOI
  6. Ghanem, 2001, Hormone replacement therapy for PADAM: Outcome and Safety (Middle East Multicenter Study), 739
  7. Rosen, 1999, Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction, Int J Impot Res, 11, 319, 10.1038/sj.ijir.3900472 · DOI
  8. Lugg, 1995, Dihydrotestosterone is the active androgen in the maintenance of nitric oxidemediated penile erection in the rat, Endocrinology, 136, 1495, 10.1210/endo.136.4.7534702 · DOI · Paper page
  9. Mills, 1999, The role of androgens in the erectile response: A 1999 perspective, Mol Urol, 3, 75
  10. Traish, 1999, Effects of castration and androgen replacement on erectile function in a rabbit model, Endocrinology, 140, 1861, 10.1210/endo.140.4.6655 · DOI · Paper page
  11. Guay, 1995, Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: Double-blind placebo-controlled trial with clomiphene citrate, J Clin Endocrinol Metab, 80, 3546
  12. Bhasin, 1998, Issues in testosterone replacement in older men, J Clin Endocrinol Metab, 83, 3435, 10.1210/jcem.83.10.5060-1 · DOI
  13. Gooren, 1998, Endocrine aspects of ageing in the male, Mol Cell Endocrinol, 145, 153, 10.1016/S0303-7207(98)00182-8 · DOI
  14. Rakic, 1997, Testosterone treatment in men with erectile disorder and low levels of total testosterone in serum, Arch Sex Behav, 5, 495, 10.1023/A:1024555805632 · DOI
  15. Papadimas, 1996, Testosterone undecanoate versus mesterolone in hypogonadal male patients, Rev Clin Pharmacol Pharmacokinet Int, 10, 3
  16. Gooren, 1994, A ten-year safety study of the oral androgen testosterone undecanoate, J Androl, 15, 212, 10.1002/j.1939-4640.1994.tb00433.x · DOI
  17. Pechersky, 2002, Androgen administration in middle-aged and ageing men: Effects of oral testosterone undecanoate on dihydrotestosterone, estradiol and prostate volume, Int J Androl, 25, 119, 10.1046/j.1365-2605.2002.00335.x · DOI
  18. Morales, 1996, Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy, Int J Impot Res, 8, 98

Cited by

Metadata

Authors
Shamloul, R., Ghanem, H., Fahmy, I., El-Meleigy, A., Ashoor, S., Elnashaar, A., & Kamel, I.
Venue
The Journal of Sexual Medicine
Publisher
Oxford University Press (OUP)
Published
2005-07-01
Volume
2
Issue
4
Pages
559-564
ISSN
  • 1743-6109
  • 1743-6095
DOI
10.1111/j.1743-6109.2005.00071.x
Cited by
69
References
7
Language
en
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.